Barinthus Biotherapeutics Appoints Dr. Sarah Gilbert CSO
Ticker: BRNS · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1828185
| Field | Detail |
|---|---|
| Company | Barinthus Biotherapeutics PLC. (BRNS) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, appointment, board-of-directors
Related Tickers: VACC
TL;DR
Sarah Gilbert is the new CSO at Barinthus. Big news for vaccine tech.
AI Summary
Barinthus Biotherapeutics plc announced on September 1, 2024, the appointment of Dr. Sarah Gilbert as Chief Scientific Officer and a new Director. Dr. Gilbert, a key figure in vaccine development, will lead the company's scientific strategy. The company also reported changes in its board of directors, including the departure of Dr. Jonathan Milner and the appointment of Mr. David M. D. Smith as a director.
Why It Matters
The appointment of Dr. Sarah Gilbert, a renowned vaccine scientist, as CSO could significantly bolster Barinthus's research and development capabilities, potentially accelerating its pipeline and attracting further investment.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution, though the appointment of a high-profile scientist like Dr. Gilbert may mitigate some risks.
Key Players & Entities
- Barinthus Biotherapeutics plc (company) — Registrant
- Dr. Sarah Gilbert (person) — Appointed Chief Scientific Officer and Director
- Dr. Jonathan Milner (person) — Departed Director
- Mr. David M. D. Smith (person) — Appointed Director
- September 1, 2024 (date) — Date of earliest event reported
FAQ
What is Dr. Sarah Gilbert's specific role at Barinthus Biotherapeutics?
Dr. Sarah Gilbert has been appointed as the Chief Scientific Officer and a new Director of Barinthus Biotherapeutics plc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on September 1, 2024.
Who has departed from the board of directors?
Dr. Jonathan Milner has departed from the board of directors.
Who is the new Director appointed to the board?
Mr. David M. D. Smith has been appointed as a director.
What was Barinthus Biotherapeutics plc's former name?
Barinthus Biotherapeutics plc was formerly known as Vaccitech plc, with a name change date of April 7, 2021.
Filing Stats: 690 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-09-05 16:05:11
Filing Documents
- tm2423440d1_8k.htm (8-K) — 27KB
- 0001104659-24-097364.txt ( ) — 245KB
- vacc-20240901.xsd (EX-101.SCH) — 3KB
- vacc-20240901_def.xml (EX-101.DEF) — 26KB
- vacc-20240901_lab.xml (EX-101.LAB) — 36KB
- vacc-20240901_pre.xml (EX-101.PRE) — 25KB
- tm2423440d1_8k_htm.xml (XML) — 5KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 1, 2024 (the "Effective Date"), Barinthus Biotherapeutics plc (the "Company") has promoted Graham Griffiths, the Company's Chief Business Officer, to Chief Operating Officer. Mr. Griffiths has been the Company's Chief Business Officer since October 2017. Prior to becoming the Company's Chief Business Officer, Mr. Griffiths served as Chief Operating Officer, co-founder and a member of the board of directors of Agalimmune Limited, a clinical stage biotechnology company, from May 2013 to September 2017. Mr. Griffiths received a BA Hons degree from Newcastle University. In connection with Mr. Griffiths promotion to the Chief Operating Officer, Mr. Griffiths' salary was increased to 336,144, effective as of the Effective Date. There are no arrangements or understandings between Mr. Griffiths and any other persons pursuant to which Mr. Griffiths was promoted to the Chief Operating Officer. There are no family relationships between Mr. Griffiths, on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Mr. Griffiths, on the one hand, and the Company, on the other. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Barinthus Biotherapeutics plc Date: September 5, 2024 By: /s/ William Enright William Enright Chief Executive Officer